Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives
Abstract
The integration of nutritional supplementation into cardiovascular disease (CVD) prevention and management represents a dynamic and often contentious field. Moving beyond traditional paradigms, recent research has sought to elucidate the precise molecular mechanisms, establish robust clinical efficacy through large-scale trials, and identify specific patient populations that may derive the greatest benefit. This review synthesizes the current evidence on key supplements—including omega-3 fatty acids, coenzyme Q10 (CoQ10), magnesium, and selenium—evaluating their roles from biochemical, translational, and clinical viewpoints. We explore the conditions under which certain supplements have transitioned from general wellness products to targeted therapeutic adjuvants, address the controversies surrounding their use, and discuss future directions for research and clinical application.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.